Oncolytics Biotech® Inc. Completes Patient Enrollment in U.K. Phase I Clinical Trial Investigating REOLYSIN® in Combination with Cyclophosphamide in Patients with Advanced Malignances
03:11 EDT 16 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
CALGARY, Aug. 16, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics")
(TSX:ONC) (NASDAQ:ONCY) today announced that it has completed patient
enrollment in its U.K. Phase I clinical trial using
intravenously-administered REOLYSIN in combination wi...
Other Sources for this Article
More From BioPortfolio on "Oncolytics Biotech® Inc. Completes Patient Enrollment in U.K. Phase I Clinical Trial Investigating REOLYSIN® in Combination with Cyclophosphamide in Patients with Advanced Malignances"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
